← All grants

High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)

National Institutes of Health · Opportunity RFA-DA-25-060

Deadline March 5, 2027 177 days left
Award range Up to $1.5M
Total program funding
PostedJanuary 17, 2024

Who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

About this opportunity

The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.

Award history — this exact opportunity

NIH RePORTER lists 8 funded awards under RFA-DA-25-060 across 6 organizations.

Awards by fiscal year 2025: 2 · 2026: 6
Award size (min / median / max) $2M / $2.3M / $2.5M

Total award obligations, not per-year amounts.

Recent awardees include: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, NORTHERN CALIFORNIA INSTITUTE/RES/EDU, UNIVERSITY OF CALIFORNIA, SAN DIEGO, YALE UNIVERSITY, FATHER FLANAGAN'S BOYS' HOME, BOSTON MEDICAL CENTER.

Source: NIH RePORTER, matched on the exact opportunity number. NIH publishes success rates by institute and activity code — source.

Portfolio context — this listing covers more than this opportunity

This opportunity is funded under Assistance Listing 93.279 (“Drug Use and Addiction Research Programs”), a broad federal program that made about 675 new awards per year over the last five fiscal years (median award $606k). Those figures describe that whole portfolio — not this specific solicitation, so we don't show them as if they were this opportunity's track record.

Applicant counts per solicitation are not published by any federal agency — no one can honestly sell you that number. NIH publishes success rates by institute and activity code — source.

Apply on grants.gov →

Don't want to hunt for grants like this one? Get free deadline alerts for your state and focus areas.

Consultant or grant writer? See the client-ready Opportunity Brief for this grant — actual award sizes vs. the advertised ceiling, who wins, printable "prepared for your client" version.

Similar grants still open